Starting this week, the t:connect mobile app will become the Tandem t:slim mobile app and get a new app icon. These changes will appear after updating to version 2.9 of the app.
Rishi Graham1, Harsimran Singh2, Gabriel Alencar2, Lars Mueller2, Michelle Manning2, Kirstin White2, Alex Wheatcroft2, KC Carmelo2, Eliah Aronoff-Spencer1, Steph Habif2, Jordan Pinsker 2
The Control-IQ Observational (CLIO) Study is an ongoing prospective, real-world evaluation of the Tandem Diabetes Care t:slim X2 insulin pump with Control-IQ technology in people with T1D. We assessed baseline HbA1c and Glucose Management Indicator (GMI) derived from sensor data from adult participants who completed the 12-month CLIO study. Adults ages ≥18 years who had ≥75% overall CGM use during this time were included in the analysis. Outcomes were analyzed using a Wilcoxon test.
In all, 1,107 participants (882 prior pump and 225 prior MDI users), median age 41 years (IQR 30-54), 57.2% female met the inclusion criteria. Median GMI was significantly lower at 12 months (7.0% [6.7-7.4]) vs. baseline HbA1c (7.2% [6.7-8.1]) (p<0.0001). Participants ages 18-30 and 46-64 showed the greatest improvement from baseline (0.3% reduction) (p<0.0001), while older adults (≥65-years) showed the lowest GMI at study end (6.9% [6.6-7.2]). Prior MDI users reported higher HbA1c at baseline (7.7% [IQR=6.8-9.0]) vs. prior pumpers (7.2% [6.7-8.0]). However, GMI at 12 months reflected glycemic improvements across all prior therapy modalities (prior MDI=7.0% [6.7-7.3]; prior pump=7.1% [6.7-7.4]) (p<0.0001). This real-world evidence demonstrates significant glycemic improvements with Control-IQ technology in adults, regardless of prior therapy modality, that are sustained long-term across diverse groups of users.
Watch the video from Dr. Jordan Pinsker for a review of the presentation delivered at the conference.